文献速递流行病学与生物统计真实世界研究与卫生经济

南部非洲一线抗逆转录病毒治疗中获得的HIV耐药突变:系统综述与贝叶斯证据合成

Acquired HIV drug resistance mutations on first-line antiretroviral therapy in Southern Africa: Systematic review and Bayesian evidence synthesis.
PubMed 文献 · J Clin Epidemiol · 2022-02-19

该系统综述纳入19个研究人群共2690例在南部非洲接受一线NNRTI方案病毒学失败的成人HIV感染者,采用贝叶斯分层Meta回归模型合成8种NRTI和7种NNRTI耐药突变的频率。结果显示,含恩曲他滨或拉米夫定的方案失败2年后M184V/I突变率高,与替诺福韦联用时为75.7%,与齐多夫定联用时为72.1%;含替诺福韦二吡呋酯时K65R突变2年患病率为52.0%。

要点

  • 一线NNRTI方案失败者中NRTI/NNRTI耐药突变常见,M184V/I在2年时可达75.7%。
  • 含替诺福韦方案失败2年时K65R突变患病率为52.0%。
  • 依非韦伦方案中K103为最常见NNRTI耐药突变,患病率57.2%。

核心结论

  • 在南部非洲一线ART失败的患者中,NRTI/NNRTI耐药突变常见,这些患者可能换用含多替拉韦但NRTI活性受损的方案,可能损害ART长期疗效。

研究设计与样本

  • 系统综述,纳入报告南部非洲成人HIV感染者一线NNRTI方案病毒学失败后耐药突变的19个研究人群,共2690例。
  • 采用贝叶斯分层Meta回归模型合成8种NRTI和7种NNRTI耐药突变的频率,并考虑ART持续时间和研究特征。

主要发现

  • 含恩曲他滨或拉米夫定的一线ART失败者中,2年时M184V/I突变率:与替诺福韦联用为75.7%(95% CrI 61.9%-88.9%),与齐多夫定联用为72.1%(95% CrI 56.8%-85.9%)。
  • 含替诺福韦二吡呋酯方案失败者中,2年时K65R突变患病率为52.0%(95% CrI 32.5%-76.8%)。
  • 依非韦伦方案中,K103为最常见的NNRTI耐药突变(57.2%,95% CrI 40.9%-80.1%),其次为V106(46.8%,95% CrI 31.3%-70.4%)。

临床怎么用

  • 作者认为,这些患者可能换用含多替拉韦但NRTI活性受损的方案,可能损害ART长期疗效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To estimate the prevalence of NRTI and NNRTI drug resistance mutations in patients failing NNRTI-based ART in Southern Africa. STUDY DESIGN: We conducted a systematic review to identify studies reporting drug resistance mutations among adult people living with HIV (PLWH) who experienced virological failure on first-line NNRTI-based ART in Southern Africa. We used a Bayesian hierarchical meta-regression model to synthesize the evidence on the frequency of eight NRTI- and seven NNRTI-DRMs across different ART regimens, accounting for ART duration and study characteristics. RESULTS: We included 19 study populations, including 2,690 PLWH. Patients failing first-line ART including emtricitabine or lamivudine showed high levels of the M184V/I mutation after 2 years: 75.7% (95% Credibility Interval [CrI] 61.9%-88.9%) if combined with tenofovir, and 72.1% (95% CrI 56.8%-85.9%) with zidovudine. With tenofovir disoproxil fumarate, the prevalence of the K65R mutation was 52.0% (95% CrI 32.5%-76.8%) at 2 years. On efavirenz, K103 was the most prevalent NNRTI resistance mutation (57.2%, 95% CrI 40.9%-80.1%), followed by V106 (46.8%, 95% CrI 31.3%-70.4%). CONCLUSIONS: NRTI/NNRTI drug resistance mutations are common in patients failing first-line ART in Southern Africa. These patients might switch to dolutegravir-based regimen with compromised NRTIs, which could impair the long-term efficacy of ART.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Hauser A, Goldstein F, Reichmuth ML, et al. Acquired HIV drug resistance mutations on first-line antiretroviral therapy in Southern Africa: Systematic review and Bayesian evidence synthesis. J Clin Epidemiol. 2022. PMID: 35192922. doi:10.1016/j.jclinepi.2022.02.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。